Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. develops and commercializes molecular diagnostic tests used to guide care in dermatologic and gastroenterological disease. Its recurring updates focus on test report volume, revenue performance, guidance, and clinical evidence for products such as DecisionDx-Melanoma and TissueCypher.
Company news also covers studies, publications, and medical-meeting presentations involving risk stratification for cutaneous melanoma, sentinel lymph node biopsy decision support through DecisionDx-Melanoma’s i31-SLNB result, and Barrett’s esophagus progression-risk assessment with TissueCypher. Financial releases frequently discuss core revenue drivers, reimbursement effects, commercial focus, and quarterly operating results.
Castle Biosciences, Inc. (NASDAQ: CSTL) will release its financial results for Q1 2022 on May 9, 2022, after market close. A conference call to discuss these results is scheduled for 4:30 p.m. ET on the same day. The company focuses on innovative diagnostic tests for diseases like skin cancers and has ongoing R&D for treatments in psoriasis and related conditions. Investors are encouraged to join the call and can access a webcast through the company's website.
Castle Biosciences (NASDAQ: CSTL) announced a study showing that melanoma patients tested with DecisionDx-Melanoma had a 27% improvement in melanoma-specific survival compared to those who were not tested. The study, part of a collaboration with the National Cancer Institute, analyzed data from 3,261 tested patients against 10,863 untested ones. Results indicated that the DecisionDx-Melanoma test delivers valuable risk stratification, aiding in personalized treatment and potentially improving patient outcomes. The findings will be presented at the 18th European Association of Dermato Oncology Congress.
Castle Biosciences (CSTL) announced the presentation of its skin cancer gene expression profile tests at the 18th European Association of Dermato Oncology Congress in Seville, Spain, from April 21-23, 2022. Key presentations include data on the 31-gene test for melanoma, the 40-gene test for high-risk squamous cell carcinoma, and advancements in diagnostic testing for melanocytic lesions, showcasing significant improvements in survival outcomes and diagnostic accuracy. These innovations aim to enhance patient management and treatment decisions.
Castle Biosciences (Nasdaq: CSTL) presented data at the RAD Conference demonstrating that its non-invasive skin scraping technique effectively collects RNA for gene expression analysis in inflammatory skin diseases, including psoriasis and atopic dermatitis. The study, involving a sample of 40 patients, highlighted a >0.99 correlation in RNA yield, suggesting reliability for future tests. Castle's ongoing 4,800 patient study aims to validate a gene expression profile test, with initial results expected in 2023 and potential launch by 2025, addressing a significant need for personalized medication selection.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced that CEO Derek Maetzold and CFO Frank Stokes will present a company overview at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 3:00 p.m. Eastern time. The presentation can be accessed via a live audio webcast on the company's website, with a replay available for two weeks afterward. Castle Biosciences focuses on innovative diagnostic tests for conditions like skin cancers and Barrett’s esophagus, aiming to improve patient care.
Castle Biosciences (Nasdaq: CSTL) has signed a definitive agreement to acquire AltheaDx, a company specializing in pharmacogenomics and mental health diagnostics, for $65 million, comprising $32.5 million in cash and $32.5 million in stock. This strategic acquisition aims to expand Castle's market presence in the estimated $8 billion U.S. pharmacogenomics market and enhance patient care solutions through the IDgenetix test for mental health conditions. Closing is expected in Q2 2022, contingent on standard conditions.
Castle Biosciences, Inc. (CSTL) announced that the Centers for Medicare & Medicaid Services (CMS) granted Advanced Diagnostic Laboratory Test (ADLT) status for its TissueCypher Barrett’s Esophagus test, effective March 24, 2022. This status allows for Medicare reimbursement, expanding access for patients at risk of esophageal cancer. TissueCypher is designed to predict the development of high-grade dysplasia and/or esophageal cancer in patients with Barrett’s esophagus. This is Castle's fourth test to achieve ADLT status.
Castle Biosciences (Nasdaq: CSTL) announced its participation in the 2022 American Academy of Dermatology Annual Meeting in Boston, showcasing its skin cancer gene expression profile tests, DecisionDx-Melanoma and DecisionDx-SCC. These tests provide independent risk stratification for melanoma and cutaneous squamous cell carcinoma, aiding in patient management. DecisionDx-Melanoma predicts metastasis risk using a 31-gene expression profile, while DecisionDx-SCC evaluates risk for high-risk patients using a 40-gene test. Presentations are scheduled for March 26 and 27, 2022, demonstrating their clinical utility.
Castle Biosciences (CSTL) presented new findings on the performance of its DecisionDx®-Melanoma test at the Society of Surgical Oncology’s 2022 Conference. The study showed that DecisionDx-Melanoma, combined with the proprietary i31-SLNB algorithm, improved predictions of sentinel lymph node (SLN) positivity in melanoma patients compared to traditional T-stage criteria. It demonstrated an Area Under the Curve (AUC) of 0.89 for low-risk tumor identification versus 0.78 for T-stage, highlighting better precision. This advancement could lead to reduced unnecessary procedures and healthcare costs.
Castle Biosciences, Inc. (NASDAQ: CSTL) has announced that CEO Derek Maetzold and CFO Frank Stokes will present at two upcoming investor conferences: the 42nd Annual Cowen Health Care Conference on March 8, 2022, at 2:50 p.m. Eastern time, and the KeyBanc Capital Markets’ Virtual Life Sciences & MedTech Investor Forum on March 22, 2022, at 9:45 a.m. Eastern time. Live webcasts will be available on the company's website, with replays accessible for two weeks post-event. Castle Biosciences focuses on innovative diagnostic tests to enhance patient care.